New Jersey lawmakers have taken a major step toward reshaping the state’s prescription drug system as the General Assembly officially approved sweeping pharmacy benefit manager reform legislation designed to increase transparency, lower medication costs, strengthen patient protections, and dramatically alter how one of the healthcare industry’s most powerful sectors operates.
The legislation, known as Assembly Bill 1502 and formally titled the Patient and Provider Protection Act, is rapidly becoming one of the most closely watched healthcare reform measures moving through Trenton in 2026. Supporters across the healthcare, life sciences, patient advocacy, and hospital sectors are describing the bill as a potentially transformative effort aimed at addressing the rising cost of prescription medications while confronting long-standing concerns surrounding the business practices of pharmacy benefit managers, commonly known as PBMs.
The Assembly’s approval marks a significant political and policy milestone in what has become a growing national debate surrounding drug pricing, healthcare middlemen, pharmacy access, and the broader economics of the pharmaceutical supply chain. Across the country, lawmakers, regulators, healthcare providers, employers, and patient advocates have increasingly scrutinized PBMs for their role in determining drug formularies, negotiating rebates, influencing medication access, and shaping the overall cost structure of prescription drug coverage.
Now, New Jersey is positioning itself at the forefront of that national conversation.
At the center of the legislation is a dramatic restructuring of how PBMs would be required to operate within the state. The bill would impose new fiduciary responsibilities on pharmacy benefit managers, legally requiring them to act in the best interests of carriers, the State Health Benefits Program, the School Employees’ Health Benefits Program, and Medicaid rather than prioritizing internal profit-driven incentives tied to prescription pricing structures.
The proposal also targets one of the most controversial elements of the PBM industry: compensation models tied directly to drug pricing, manufacturer rebates, and prescription utilization volume. Critics of the current system argue that these financial arrangements create incentives for PBMs to favor more expensive medications because larger drug prices often generate larger rebates and increased revenue opportunities.
Assembly Bill 1502 seeks to fundamentally alter that structure by moving PBM compensation toward a flat-fee administrative model intended to remove financial incentives tied to medication pricing itself. Supporters argue that shifting toward flat-fee transparency could create a more patient-centered system focused on affordability and appropriate care rather than maximizing rebate-driven profits.
The legislation also includes broad new transparency requirements surrounding PBM fees, broker payments, pricing structures, and reimbursement arrangements. Advocates say those provisions are essential because the PBM industry has historically operated through highly complex and often opaque financial systems that many healthcare providers, employers, and patients struggle to fully understand.
The growing public frustration surrounding prescription costs has intensified scrutiny of PBMs nationwide. Although PBMs were originally intended to help negotiate lower drug prices on behalf of insurers and health plans, critics increasingly argue that consolidation within the industry has concentrated enormous market power into the hands of a small number of corporations with limited transparency and substantial influence over which medications patients receive and how much they pay.
Federal regulators have also begun examining those concerns more aggressively. Lawmakers supporting the New Jersey legislation have pointed directly to a 2024 interim report issued by the Federal Trade Commission which found that the nation’s six largest PBMs collectively manage nearly 95 percent of all prescriptions filled in the United States. That level of market concentration has fueled concerns about competition, pricing practices, pharmacy access, and the broader balance of power within the healthcare system.
Assemblyman Roy Freiman, representing New Jersey’s 16th Legislative District and serving as one of the bill’s primary sponsors, has emerged as one of the leading voices behind the reform effort. Freiman has consistently framed the legislation as a patient-first initiative focused on affordability, transparency, and access to medications for New Jersey families.
According to supporters of the measure, the bill directly addresses concerns that patients often face unnecessary barriers when attempting to access affordable prescriptions while independent pharmacies struggle to compete against vertically integrated healthcare systems controlled by large PBMs and affiliated pharmacy chains.
One of the legislation’s most significant provisions would restrict PBMs from steering patients toward affiliated pharmacies or excluding pharmacies willing to meet network participation terms. Independent pharmacies across New Jersey have increasingly argued that current PBM practices disadvantage smaller local operators while steering business toward PBM-owned pharmacy networks.
That issue has become particularly important in many suburban, rural, and underserved communities where independent pharmacies often function as critical healthcare access points beyond simply dispensing medication. In many New Jersey towns, local pharmacies remain deeply integrated into community healthcare infrastructure, serving seniors, chronic-care patients, and residents who rely on personal relationships and direct access to pharmacists.
Supporters of the legislation argue that preserving pharmacy competition and preventing anti-competitive steering practices could help protect healthcare access while strengthening local healthcare ecosystems throughout the state.
The bill would also establish new reimbursement and formulary standards designed to prevent PBMs from favoring higher-cost brand-name medications when lower-cost generic or biosimilar alternatives may be available. Biosimilars in particular have become an increasingly important part of national healthcare cost discussions because they often provide significantly more affordable alternatives to expensive biologic medications used in treating chronic and complex conditions.
Healthcare advocates supporting the legislation believe reforming PBM incentives could play a meaningful role in reducing long-term healthcare costs while improving medication accessibility for patients managing chronic illnesses, rare diseases, or high-cost treatment regimens.
The Assembly vote has also generated unusually broad support from organizations representing multiple sectors of New Jersey’s healthcare economy, including life sciences, hospitals, patient advocacy groups, and healthcare policy organizations.
The HealthCare Institute of New Jersey, one of the state’s most influential healthcare and life sciences organizations, publicly backed the measure following the Assembly vote. HINJ President and CEO Chrissy Buteas emphasized New Jersey’s global role within pharmaceutical innovation and medical research while arguing that PBM business practices should not artificially inflate costs for patients.
New Jersey has long carried the nickname “The Medicine Chest of the World” because of its extraordinary concentration of pharmaceutical, biotechnology, and life sciences companies. The state remains home to some of the world’s largest pharmaceutical firms, research institutions, and drug development operations, making healthcare affordability and pharmaceutical policy especially significant issues within New Jersey’s broader economic and public health landscape.
BioNJ, another major life sciences advocacy organization, also strongly endorsed the legislation, praising the Assembly’s action while signaling continued pressure on the State Senate to advance companion legislation currently awaiting further movement. BioNJ leadership framed the bill as an important step toward improving patient access to medications while confronting PBM business practices that many advocates argue have contributed to rising healthcare costs and treatment delays.
The political momentum surrounding the legislation reflects growing bipartisan concern nationally over prescription affordability and the role of intermediaries within the healthcare system. While debates over drug pricing have existed for decades, PBMs themselves have increasingly moved into the public spotlight as policymakers attempt to better understand why medication costs continue escalating even as pharmaceutical innovation advances rapidly.
For New Jersey families, employers, and healthcare providers, the stakes surrounding the legislation are substantial. Rising prescription costs continue affecting household budgets, insurance premiums, employer healthcare spending, and long-term public healthcare expenditures. Businesses providing employee health coverage have increasingly voiced frustration regarding pharmacy benefit complexity and escalating pharmacy costs that remain difficult to predict or fully explain.
Hospitals and healthcare providers have also joined the debate. Leaders within New Jersey’s healthcare system argue that opaque PBM practices can complicate patient treatment, delay medication access, and create administrative burdens that ultimately impact patient care outcomes.
The legislation’s supporters believe increased transparency and fiduciary accountability could help restore greater balance to the system while making healthcare spending more predictable and patient-focused.
At the same time, the bill enters a politically and economically complex environment where major national PBMs and healthcare corporations continue wielding enormous influence within both the healthcare system and legislative policy discussions. Opponents of aggressive PBM reform in other states have sometimes argued that PBMs help negotiate lower prices overall and that sweeping regulatory changes could produce unintended consequences within insurance markets.
Those debates are expected to intensify as the legislation advances further through the New Jersey Senate, where companion bill S-2345 remains under consideration.
Regardless of the eventual legislative outcome, the Assembly’s approval of the Patient and Provider Protection Act signals that New Jersey is prepared to play a leading role in one of the most important healthcare policy battles unfolding nationally. Questions surrounding prescription affordability, healthcare transparency, patient access, pharmacy competition, and pharmaceutical supply chain accountability are no longer peripheral policy issues. They are rapidly becoming central to broader debates about the future structure of American healthcare itself.
For New Jersey residents struggling with rising prescription costs, the legislation represents the possibility of a healthcare system where transparency, affordability, and patient access receive greater priority than opaque financial arrangements and rebate-driven incentives. For independent pharmacies, it represents a potential lifeline within an increasingly consolidated industry. For healthcare advocates and providers, it reflects growing recognition that the economics of prescription drug distribution can no longer remain hidden behind layers of complex intermediaries.
As the bill continues moving through the legislative process, New Jersey now finds itself at the center of a national effort to rethink how prescription drug systems function — and whether meaningful reform can finally shift healthcare priorities back toward the patients those systems were originally intended to serve.
